CN104869983A - 醋酸格拉替雷的透粘膜给药 - Google Patents

醋酸格拉替雷的透粘膜给药 Download PDF

Info

Publication number
CN104869983A
CN104869983A CN201380067083.XA CN201380067083A CN104869983A CN 104869983 A CN104869983 A CN 104869983A CN 201380067083 A CN201380067083 A CN 201380067083A CN 104869983 A CN104869983 A CN 104869983A
Authority
CN
China
Prior art keywords
oral tablet
tablet
weight
present
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067083.XA
Other languages
English (en)
Chinese (zh)
Inventor
厄休拉·杰斯特
斯蒂芬·施威策尔
玛蒂娜·伯格
拉尔夫·斯蒂芬
杰拉德·休伯
坦娅·普利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN104869983A publication Critical patent/CN104869983A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380067083.XA 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药 Pending CN104869983A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
US61/745,226 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (1)

Publication Number Publication Date
CN104869983A true CN104869983A (zh) 2015-08-26

Family

ID=50979257

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380067083.XA Pending CN104869983A (zh) 2012-12-21 2013-12-20 醋酸格拉替雷的透粘膜给药

Country Status (15)

Country Link
US (1) US20160193276A1 (enExample)
EP (1) EP2934492A4 (enExample)
JP (1) JP2016503803A (enExample)
KR (1) KR20150111918A (enExample)
CN (1) CN104869983A (enExample)
AU (1) AU2013361053A1 (enExample)
BR (1) BR112015014095A2 (enExample)
CA (1) CA2895359A1 (enExample)
EA (1) EA201591188A1 (enExample)
HK (2) HK1214523A1 (enExample)
IL (1) IL239280A0 (enExample)
MX (1) MX2015007678A (enExample)
SG (1) SG11201504422XA (enExample)
WO (1) WO2014100639A1 (enExample)
ZA (1) ZA201505049B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106924175A (zh) * 2015-12-29 2017-07-07 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
WO2017138645A1 (ja) * 2016-02-12 2017-08-17 テイカ製薬株式会社 乾式造粒物及び該乾式造粒物を含有する固形製剤並びにそれらの製造方法
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055568A1 (en) * 2000-02-18 2001-12-27 Adrian Gilbert Oral, nasal and pulmonary dosage formulations of copolymer 1
US20030143257A1 (en) * 2001-07-10 2003-07-31 Moshe Fleshner-Barak Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
CA2596664A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
AU2005338461A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
BRPI0620578A2 (pt) * 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
EP2526934B1 (en) * 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055568A1 (en) * 2000-02-18 2001-12-27 Adrian Gilbert Oral, nasal and pulmonary dosage formulations of copolymer 1
US20030143257A1 (en) * 2001-07-10 2003-07-31 Moshe Fleshner-Barak Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
庄越，曹宝成等: "《实用药物制剂技术》", 31 January 1999, 人民卫生出版社 *
罗明生，高天惠: "《药剂辅料大全》", 31 March 1993, 四川科学技术出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106924175A (zh) * 2015-12-29 2017-07-07 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物

Also Published As

Publication number Publication date
CA2895359A1 (en) 2014-06-26
JP2016503803A (ja) 2016-02-08
AU2013361053A1 (en) 2015-07-30
SG11201504422XA (en) 2015-07-30
EA201591188A1 (ru) 2016-04-29
IL239280A0 (en) 2015-07-30
WO2014100639A1 (en) 2014-06-26
HK1214134A1 (zh) 2016-07-22
US20160193276A1 (en) 2016-07-07
EP2934492A4 (en) 2016-08-17
EP2934492A1 (en) 2015-10-28
KR20150111918A (ko) 2015-10-06
MX2015007678A (es) 2015-09-07
ZA201505049B (en) 2016-10-26
HK1214523A1 (zh) 2016-07-29
BR112015014095A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
CN104869983A (zh) 醋酸格拉替雷的透粘膜给药
ES2507579T3 (es) Composición farmacéutica para el tratamiento del insomnio mediante administración sublingual
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
AU2007287549B2 (en) Galenic formulations of aliskiren
CN104812378B (zh) 固体剂型
TW200815048A (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
JP2013509403A (ja) 速溶性固体剤形
WO2007096906A2 (en) Novel buccoadhesive compositions and process of preparation thereof
JP2018517715A5 (enExample)
Raju et al. Formulation and in-vitro evaluation of buccal tablets of metoprolol tartrate
JP2010523678A5 (enExample)
CN116615243A (zh) 使用右美托咪啶盐酸盐治疗躁郁症和精神病
CN1658898B (zh) 包含培哚普利的口腔分散药物组合物
JP5064226B2 (ja) 不眠症の治療において有用な新規な製剤処方
US20150328277A1 (en) Oral transmucosal delivery of glatiramer acetate
EP1496868A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
KR101697773B1 (ko) 독소필린을 포함하는 변형 방출 조성물
TW200800155A (en) Gastric retentive gabapentin dosage forms and methods for using same
WO2019018338A1 (en) NASAL COMPOSITION COMPRISING A MUCOADHESIVE POLYMER
AU2013200682B1 (en) Fast Dissolving Solid Dosage Form
CN114788817A (zh) 苯海拉明药物组合物
Tarun et al. Drug Delivery via the Buccal Patch–A Novel Approach
CN115531326A (zh) 一种卡巴拉汀微片及其制备方法
Doshi Preparation and evaluation of intraoral drug delivery system for the treatment of asthma
JP2003095936A (ja) 消化器用医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1214134

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150826

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1214134

Country of ref document: HK